Cabozantinib and Pembrolizumab in Metastatic Pancreas

• Status: Recruiting
• Trial end date: 2033-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Joseph Kim
• Collaborators: Exelixis; Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• Diagnosis of pancreatic ductal adenocarcinoma

• Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies

• Patients must have adequate organ function

Exclusion Criteria:

• Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation

• Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention

• Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation

• Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy

• Clinically significant cardiovascular disease

• Uncontrolled hypertension

• Inability to swallow tablets